 final report french multicent phase II studi nitrosourea fotemustin evalu patient dissemin malign melanoma patient cerebr metastas sixty-nin patient histolog evid dissemin malign melanoma patient cerebr metastas phase II studi nitrosourea fotemustin treatment regimen hour IV infus week consecut week rest period induct therapi patient mainten therapi week diseas fifty-thre patient evalu respons complet respons partial respons world health organ criteria object respons rate confid interv respons cerebr viscer nonviscer metastat site median durat respons week rang week object respons rate untreat patient patient main toxic hematolog delay revers leukopenia and/or thrombopenia object respons rate untreat patient activ cerebr metastas small amount extra-hematolog toxic fotemustin effect drug dissemin malign melanoma